I Like This ReleaseGood afternoon all, investors will read this release and interpret it in their own way. I see this as very positive development and one that will provide a catalyst for our SP in the near term. The BLA submission is delayed for up to three additional months, I am very pleased to see the company working in fully collaboration with the FDA and staying with a persistent effort to submit a complete and flawless BLA. With clear commercial assessment analysis conducted by Medical Marketing Economics, further guidance from the FDA and the engagement of Bristol Capital I see momentum building as Bristol gets rolling. Now estimated at over $400mil in the US will attract some interest. Go Telesta!